Neurocast.ai Completes FDA Device Registration, Unlocking U.S. Launch of Brain Health Platform
Amsterdam, Netherlands--(Newsfile Corp. - May 19, 2025) - Neurocast.ai, a digital health company transforming brain health monitoring, has officially registered its passive monitoring platform with the U.S. Food and Drug Administration (FDA) under a 510(k)-exempt classification. This milestone enables Neurocast to bring its breakthrough technology to the U.S. market, starting...
2025-05-19 6:02 AM EDT | Neurocast
Izotropic's U.S. FDA Regulatory Pathway Greenlit, Company Provides Corporate Update
- Regulatory alignment with FDA confirmed, clearing path to pivotal U.S. clinical trial -- 150-page strategic business plan and advanced financial models completed -- Investor outreach launched to fund clinical execution and market entry -Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - May 16, 2025) - Izotropic Corporation (CSE: IZO)...
2025-05-16 10:36 PM EDT | Izotropic Corporation
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that it has granted 600,000 incentive stock options (the "Options") to directors and employees of the company. The Options are exercisable at a...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-16 4:30 PM EDT | NervGen Pharma Corp.
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical studyMarlborough, Massachusetts--(Newsfile Corp. - May 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-15 4:15 PM EDT | Phio Pharmaceuticals Corp.
BioHarvest Sciences Reports First Quarter 2025 Financial Results
Rehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures...
Biotechnology, Pharmaceuticals, Health
2025-05-15 4:05 PM EDT | BioHarvest Sciences Inc.
AquaBounty Technologies Announces First Quarter 2025 Financial Results
Harvard, Massachusetts--(Newsfile Corp. - May 15, 2025) - AquaBounty Technologies, Inc. (NASDAQ: AQB) ("AquaBounty" or the "Company"), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced the Company's financial results for the first quarter ended March 31, 2025.First Quarter 2025 HighlightsNet income for the quarter ended...
Agriculture, Biotechnology, Food / Beverages
2025-05-15 10:57 AM EDT | AquaBounty Technologies, Inc.
Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial
Halifax, Nova Scotia--(Newsfile Corp. - May 15, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the successful completion of bacterial endotoxin testing ("BET") on Sona's uniquely biocompatible gold nanorods using the Limulus Amebocyte Lysate ("LAL") method at a leading global provider of...
2025-05-15 9:32 AM EDT | Sona Nanotech Inc.
Nextleaf Shares Commercial Update Featuring Market Expansion Through Entry into Province of Quebec
Vancouver, British Columbia--(Newsfile Corp. - May 15, 2025) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), an innovation-driven life sciences company and licensed cannabis processor, is excited to share a commercial update including 20 new product listings in major markets nationally across 4...
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2025-05-15 9:00 AM EDT | Nextleaf Solutions Ltd.
European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress
Toronto, Ontario--(Newsfile Corp. - May 15, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the European Hematology Association ("EHA") has accepted Telo Genomics'...
2025-05-15 8:30 AM EDT | Telo Genomics Corp.
NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates
Completed last subject, last visit in the chronic cohort, data readout targeted for early June 2025Vancouver, British Columbia--(Newsfile Corp. - May 15, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuro-reparative therapeutics, today reported its financial and operational results for the first...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-15 7:30 AM EDT | NervGen Pharma Corp.
PreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc., Expanding Its Digital Presence to Enhance Accessibility and Awareness of Innovative Therapies
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is thrilled to announce that BioGene Therapeutics Inc. ("BioGene"), a majority-owned subsidiary of...
Biotechnology, Pharmaceuticals, Health
2025-05-14 7:00 AM EDT | PreveCeutical Medical Inc.
Three Finalists Announced for the 2025 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - May 14, 2025) - Bloom Burton & Co. is pleased to announce the finalists for the 2025 Bloom Burton Award. Bestowed annually and nominated by the public at large, the Bloom Burton Award honours an individual who made the greatest contribution to Canada's innovative healthcare industry...
Technology, Biotechnology, Investment Banking, Health
2025-05-14 7:00 AM EDT | Bloom Burton & Co. Inc.
Sharp Therapeutics Corp. Nominates Clinical Candidate for Gaucher's Disease
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces that it has nominated a small molecule compound from its GBA program for clinical development in Gaucher's...
2025-05-13 5:05 PM EDT | Sharp Therapeutics Corp.
Neural Therapeutics Announces RSU and Options Grant
Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, announces that the Board of Directors approved the grant of 2,720,000 restricted share...
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-05-13 4:31 PM EDT | Neural Therapeutics Inc.
Envoy Medical Achieves Clinical Trial Milestone and is Optimistic About Expansion into Final Stage of Trial
White Bear Lake, Minnesota--(Newsfile Corp. - May 13, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announces achieving the important milestone of successful activation of all 10 study participants' fully implanted...
Biotechnology, Healthcare and Hospitals
2025-05-13 9:15 AM EDT | Envoy Medical, Inc.
Adaptimmune Reports Q1 Financial Results and Provides Business Update
TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in Q1 2025Instituting 2025 Tecelra full year sales guidance of $35-$45 millionLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026
Biotechnology, Healthcare and Hospitals
2025-05-13 7:30 AM EDT | Adaptimmune Therapeutics PLC
Aires Activates Second Sponsorship Integration with NASCAR Driver Chad Finchum
Integration includes the NASCAR All-Star Open on Sunday, May 18 and NASCAR Cup Series Cracker Barrel 400 Race on Sunday, June 1Installation of Aires products will optimize the electromagnetic field (EMF) environment surrounding Finchum & crewGarage 66 Ford Mustang, Finchum & crew will prominently showcase Aires brand marksNASCAR broadcasts reach...
2025-05-13 6:00 AM EDT | American Aires Inc.
Marvel Biosciences Announces Closing of Private Placement
Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces that, further to its press releases of March 28, 2025 and May 2, 2025, it has closed its non-brokered private placement (the "Offering")....
2025-05-12 6:05 PM EDT | Marvel Biosciences Corp.
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal...
Biotechnology, Pharmaceuticals
2025-05-12 6:00 PM EDT | InMed Pharmaceuticals
Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share
Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), per the Company's February 4, 2025 news release, closed the previously announced USD $336,500 non-brokered private placement, issuing 1,634,466 Common Shares at CAD $0.295 each to CytoImmune Therapeutics LLC, following...
Biotechnology, Pharmaceuticals, Health
2025-05-12 9:00 AM EDT | Hemostemix Inc.